At a glance
ClinicalIndex Comparison RecordPhase 1Completed· 26 enrolled
Drug / intervention
LY3832479 +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 1, Randomized, Placebo-Controlled Study to Evaluate the Tolerability, Safety, Pharmacokinetics, and Immunogenicity of LY3832479 Given as a Single Intravenous Dose in Healthy Participants
In Brief
A Phase 1 clinical trial evaluating LY3832479 and Placebo for Healthy. Completed, enrolled 26 participants across 1 site.
Detailed Summary
The main purpose of this study is to learn more about the safety of LY3832479 and any side effects that might be associated with it. Blood tests will be done to measure how much LY3832479 is in the bloodstream and how long it takes the body to eliminate it. Participation could last up to 16 weeks and may include up to 10 visits to the study center.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHealthy
CountriesUnited States
Collaborators--
Timeline
Phase 1CompletedFinished
202120222023202420252026
Enrollment StartJun 2020
First PostedJun 2020
Primary CompletionOct 2020
TodayJul 2026
First PostedJun 22, 2020
Enrollment StartJun 19, 2020
Primary CompletionOct 2, 2020
TodayJul 2, 2026
Enrollment to primary: 3 monthsPosted 6.0 years ago
Interventions
LY3832479drug
Administered IV.
Placebodrug
Administered IV.